Virtu KCG Holdings’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Virtu KCG Holdings’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$50K	Sell	196 -55	-22%	-$14.8K	﹤0.01%	2594
2017 Q1	$83K	Buy	251 +153	+156%	+$70.9K	﹤0.01%	2738
2016 Q4	$59K	Buy	+98	New	+$104K	﹤0.01%	3054
2016 Q2	–	Sell	-38	Closed	-$48K	–	3412
2016 Q1	$48K	Buy	+38	New	+$54.1K	﹤0.01%	2468
2015 Q3	–	Sell	-89	Closed	-$90K	–	3917
2015 Q2	$90K	Buy	89 +41	+85%	+$44.2K	﹤0.01%	2938
2015 Q1	$49K	Buy	+48	New	+$158K	﹤0.01%	2831
2014 Q3	–	Sell	-31	Closed	-$120K	–	4173
2014 Q2	$120K	Sell	31 -1	-3%	-$3.77K	﹤0.01%	3252
2014 Q1	$176K	Buy	+32	New	+$169K	﹤0.01%	3049

Other funds holding NBSE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Virtu KCG Holdings's NBSE Position: Q2 2017 in Review

Virtu KCG Holdings reduced its NeuBase Therapeutics, Inc. Common Stock (NBSE) stake by 22% in Q2 2017, selling an estimated $14.8K and leaving 196 shares worth $50K. The position accounts for ﹤0.01% of the portfolio, ranked #2594.

Virtu KCG Holdings first reported a position in NBSE in Q1 2014 and has held it in 8 quarters since. The position peaked at $176K in Q1 2014. 38 funds tracked by Wall St. Rank hold NBSE as of Q2 2017.

Virtu KCG Holdings held 196 shares of NeuBase Therapeutics, Inc. Common Stock worth $50K as of Q2 2017.
Virtu KCG Holdings sold 55 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $14.8K.
NeuBase Therapeutics, Inc. Common Stock made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2594 holding.
Virtu KCG Holdings first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2014 and has held it in 8 quarters since.
Virtu KCG Holdings's NeuBase Therapeutics, Inc. Common Stock position peaked at $176K in Q1 2014.
38 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.